DR blindness not caused by DR

Article

Visual loss in subjects with diabetic retinopathy (DR) is caused by factors other than the disease, according to study results published in the September issue of Investigative Ophthalmology & Visual Science.

Visual loss in subjects with diabetic retinopathy (DR) is caused by factors other than the disease, according to study results published in the September issue of Investigative Ophthalmology & Visual Science.

Lohrasb Ahmadian, MD, MPH, MSc, and Robert Massof, PhD, FAAO of the Lions Vision Research and Rehabilitation Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, US conducted a retrospective study assessing reading, mobility, visual motor and visual information processing. For each of these metrics, the researchers monitored the results from DR patients (n=114) and case-matched them with those of patients suffering from other ocular diseases (n=114) who were of an equivalent age (19–90 years; mean, 67.5), visual acuity (VA; mean, 0.7 logMAR), gender and general health.

After adjusting for multiple comparisons, the researchers found no statistically significant difference in any of the four metrics for the matched pairs. There was, moreover, no statistically significant difference between matched pairs when comparing two further parameters: goal-level vision-related functional ability and total visual ability.

The researchers concluded that the disease process itself is not the root cause of visual impairment in DR subjects, and that it is more likely that the visual impairment that these patients experience is caused by the impact of the disease in their daily lives.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.